Synaptiq Therapeutics is an independent, privately held clinical-stage biotechnology company established in 2026 to advance SYN-001. The program was advanced by Nobias as NB-001 through a randomized, double-blind, placebo-controlled Phase II clinical trial that demonstrated a favorable safety and tolerability profile together with positive efficacy signals and received both FDA Orphan Drug Designation and Rare Pediatric Disease Designation. Building on this strong clinical and regulatory foundation, Synaptiq was created to provide a dedicated entity focused on advancing SYN-001 through the next stage of clinical development.